Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Dynavax Technologies (DVAX)

Dynavax Technologies (DVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,760,183
  • Shares Outstanding, K 131,455
  • Annual Sales, $ 232,280 K
  • Annual Income, $ -6,390 K
  • EBIT $ -11 M
  • EBITDA $ -20 M
  • 60-Month Beta 1.34
  • Price/Sales 7.65
  • Price/Cash Flow N/A
  • Price/Book 2.60

Options Overview Details

View History
  • Implied Volatility 44.51% ( +6.15%)
  • Historical Volatility 48.36%
  • IV Percentile 76%
  • IV Rank 59.83%
  • IV High 66.80% on 10/30/24
  • IV Low 11.34% on 09/23/24
  • Put/Call Vol Ratio 0.04
  • Today's Volume 1,432
  • Volume Avg (30-Day) 767
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 17,659
  • Open Int (30-Day) 13,289

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.04
  • Number of Estimates 3
  • High Estimate 0.06
  • Low Estimate 0.01
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.67 +14.43%
on 10/28/24
13.89 -12.10%
on 11/11/24
+1.45 (+13.48%)
since 10/15/24
3-Month
10.12 +20.65%
on 10/10/24
13.89 -12.10%
on 11/11/24
+0.87 (+7.67%)
since 08/15/24
52-Week
9.74 +25.36%
on 08/06/24
15.01 -18.65%
on 01/04/24
-1.32 (-9.76%)
since 11/15/23

Most Recent Stories

More News
Dynavax Technologies (DVAX) Q3 2024 Earnings Call Transcript

DVAX earnings call for the period ending September 30, 2024.

DVAX : 12.21 (-8.81%)
Dynavax Technologies: Q3 Earnings Snapshot

Dynavax Technologies: Q3 Earnings Snapshot

DVAX : 12.21 (-8.81%)
Dynavax Technologies (DVAX) Q2 2024 Earnings Call Transcript

DVAX earnings call for the period ending June 30, 2024.

DVAX : 12.21 (-8.81%)
Dynavax Technologies: Q2 Earnings Snapshot

Dynavax Technologies: Q2 Earnings Snapshot

DVAX : 12.21 (-8.81%)
3 'Strong Buy' Small-Caps With 27% to 146% Upside Potential

This article highlights three small-cap stocks with 'Strong Buy' ratings that offer substantial upside potential of 27% to 146% and are poised to benefit from current market trends.

HI : 32.77 (-2.76%)
HLX : 9.95 (-3.49%)
DVAX : 12.21 (-8.81%)
$IQY : 1,462.97 (-0.92%)
Dynavax Technologies (DVAX) Q1 2024 Earnings Call Transcript

DVAX earnings call for the period ending March 31, 2024.

DVAX : 12.21 (-8.81%)
Dynavax Technologies: Q1 Earnings Snapshot

Dynavax Technologies: Q1 Earnings Snapshot

DVAX : 12.21 (-8.81%)
Dynavax Technologies (DVAX) Q4 2023 Earnings Call Transcript

DVAX earnings call for the period ending December 31, 2023.

DVAX : 12.21 (-8.81%)
Why Vera Therapeutics Stock Soared by 22% This Week

Executive changes and a bullish analyst take combined to boost sentiment on the company.

AMGN : 283.61 (-4.16%)
DVAX : 12.21 (-8.81%)
VERA : 46.26 (-5.59%)
Dynavax Technologies (DVAX) Q3 2023 Earnings Call Transcript

DVAX earnings call for the period ending September 30, 2023.

DVAX : 12.21 (-8.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development...

See More

Key Turning Points

3rd Resistance Point 14.30
2nd Resistance Point 13.85
1st Resistance Point 13.03
Last Price 12.21
1st Support Level 11.76
2nd Support Level 11.31
3rd Support Level 10.49

See More

52-Week High 15.01
Fibonacci 61.8% 13.00
Fibonacci 50% 12.38
Last Price 12.21
Fibonacci 38.2% 11.75
52-Week Low 9.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar